Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosentini, Deborah, Grisanti, Salvatore, Dalla Volta, Alberto, Laganà, Marta, Fiorentini, Chiara, Perotti, Paola, Sigala, Sandra, Berruti, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280582/
https://www.ncbi.nlm.nih.gov/pubmed/30400026
http://dx.doi.org/10.1530/EC-18-0398
Descripción
Sumario:Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.

Ejemplares similares